At best, the PD1-Vaxx + atezolizumab trial has seen the combination dosed in 5 patients out of a planned ~48. In reality, it's likely that it hasn't made is past the PD1-Vaxx monotherapy arm. You wouldn't terminate this trial and indicate you're looking to offload this platform if the results had been at all positive.
IMU will have canned this study to reduce the liabilities ($$$) on the B Cell platform so that it looks more enticing to an acquirer. Suspect the B Cell platform is flogged off for cents on the dollar, if they can find a buyer.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)